Doximity announced significant growth in its AI Search advertising product, reaching eight-figure bookings and expanding its health system customer base. The company is also moving into clinical decision support with new tools and integrations, indicating strong product adoption and potential for future revenue growth.
Doximity reported that its AI Search advertising product has achieved eight-figure bookings, with 16 of the top 20 pharmaceutical companies now using it. This indicates strong market penetration and revenue generation from its AI offerings. The company also expanded its health system customer base from 165 to over 190 in one quarter and introduced a new clinical decision support tool, 'DoseCheck,' integrating content from Wolters Kluwer’s UpToDate. This news is positive for Doximity as it demonstrates successful product development, increased customer adoption, and diversification into new service areas, potentially leading to sustained growth. For traders, this suggests a positive short-term outlook for DOCS due to strong operational performance and long-term potential from expanding AI capabilities in healthcare.